Related Experiment Video

Updated: Jul 16, 2026

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections

James A Driscoll1, Steven L Brody, Marin H Kollef

  • 1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.

Drugs
|March 6, 2007
PubMed

Insights

Pseudomonas aeruginosa infections are a growing concern due to increasing antimicrobial resistance. Effective treatment requires prevention, source control, and appropriate antibiotics, with new options on the horizon.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Pseudomonas aeruginosa is a significant bacterial pathogen causing infections in hospitalized patients, immunocompromised individuals, and those with cystic fibrosis.
  • Surveillance indicates rising antimicrobial resistance, including carbapenem and multidrug resistance, in nosocomial P. aeruginosa infections.

Purpose of the Study:

  • To review the mechanisms of antimicrobial resistance and virulence in Pseudomonas aeruginosa.
  • To outline effective treatment strategies for P. aeruginosa infections, emphasizing prevention, source control, and appropriate antibiotic use.
  • To discuss the role of antibacterial de-escalation and the future availability of novel anti-pseudomonal agents.

Main Methods:

  • Literature review and synthesis of current research on Pseudomonas aeruginosa.
  • Analysis of surveillance data trends regarding antimicrobial resistance patterns.
  • Examination of established and emerging treatment modalities for P. aeruginosa infections.

Main Results:

  • Key resistance mechanisms include efflux pumps, beta-lactamases, and porin downregulation.
  • Virulence factors involve secreted toxins and biofilm formation.
  • Increasing trends of carbapenem and multidrug resistance necessitate careful treatment selection.

Conclusions:

  • Effective management of P. aeruginosa infections hinges on prevention, source control, and judicious antibiotic administration.
  • Antibacterial de-escalation is recommended when clinically appropriate and pathogen susceptibilities are known.
  • While challenging, multidrug-resistant strains may be treated with agents like colistin, with newer therapies anticipated.

More Related Videos

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae06:04

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae

Published on: June 13, 2025

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection06:56

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

Published on: February 20, 2020

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps: